Denise Neves Gameiro, Author at Labiotech.eu

About

Journalist intern. Studied Bioengineering in Porto and was a lab rat in Sweden. Enjoying Berlin and the company of Labiotech’s resident plants.

Articles by Denise Neves Gameiro

leo pharma astrazeneca dermatology biologics

News and Trends 4 Jul 2016

Danish Pharma enters in the Biologics arena with Antibody Buy-out

Leo Pharma is acquiring rights to two of AstraZeneca‘s candidates. The targeted indications are atopic dermatitis and psoriasis – autoimmune conditions getting more and more attention. Based near Copenhagen (Denmark), Leo Pharma specializes in dermatological therapies – particularly topical treatments. The company is not shy about its acquisitions, having entered a €675M deal to buy Japanese […]

July 4, 2016 - 3 minutesmins - By Denise Neves Gameiro

morphosys thrombosis phaseI novartis hucal

News and Trends 4 Jul 2016

Novartis delivers German Biotech’s 12th Antibody to Clinics

MorphoSys keeps up its impressive productivity in feeding pipelines. Its 12th antibody in its Novartis collaboration has just reached clinical development. After presenting results for two of its wholly-owned candidates at ASCO 2016 (you can get an insider look into ASCO from the team), MorphoSys is receiving good news on the collaborations’ front. One of the […]

July 4, 2016 - 2 minutesmins - By Denise Neves Gameiro

abivax ceo ehrlich interview hiv hepatitis

News and Trends 4 Jul 2016

“We have one of the World’s Most Advanced Functional HIV Cures under development”

Abivax has recently announced that it’s likely that its most advanced program in hepatitis B will fail its Phase III trials. That’s really bad news for the company, and stocks have plummeted by around 50%. But what does this really mean for the future of Abivax? To find out, I had a chat with the company’s CEO Hartmut […]

July 4, 2016 - 5 minutesmins - By Denise Neves Gameiro

kathy high bioart biomedical research blood rats

News and Trends 2 Jul 2016

Blood Wars and Celebrating the Unsung Rats of Science with #BioArt

Kathy High is an American artist exploring the areas of technology, science, speculative fiction and art. She does this with installations and workshops – including one where the audience’s blood fights each other. Kathy High studied fine arts, English literature, video and photography at New York. On top of having a lot of well-known work in […]

July 2, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 1 Jul 2016

37% of all Living Nobel Laureates urged Greenpeace to stop anti-GMO campaigns

The GMO debate is back into mainstream news, as 110 Nobel laureates (out of the 297 living) signed a ‘cease and desist’ open letter to Greenpeace. The target is its anti-GMO campaign, which they deem anti-scientific. And Golden Rice is the spearhead of the accusations… How many poor people in the world must die before […]

July 1, 2016 - 5 minutesmins - By Denise Neves Gameiro

News and Trends 30 Jun 2016

Key German Hospital to start a Phase I trial in TCR Cell Therapy

Medigene will make its clinical debut in TCR, in a collaboration with the Max Delbrück Centre and the Charité Hospital in Berlin. The planned Phase I trial focus on the blood cancer multiple myeloma. Based near Munich (Germany), Medigene develops different anti-cancer cell therapies, as we recently discussed in an interview with former CFO […]

June 30, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 30 Jun 2016

11 Hot Companies to Meet this Year at BioSpain

Spain has a lot of great stuff – paella, tapas, siesta! But how is Spanish biotech doing? With BioSpain 2016 approaching, we took a look at some of the most important biotechs operating in Spain and attending the event. Bonus: here is a promotional code to have a discount of 10% on your ticket BIO2016 As one […]

June 30, 2016 - 5 minutesmins - By Denise Neves Gameiro

affiris peptide vaccine affitope cholesterol

News and Trends 29 Jun 2016

Vienna-based Biotech raises €10M to fight Metabolic diseases and Parkinson’s

AFFiRiS has received €10M from previous investors and one additional backer, adding up to €130M in total funding (half from grants and licensing incomes). This money fuels a pipeline in cardiometabolic and neurodegenerative diseases as more candidates break into clinical development. Based at the Campus Vienna Biocenter (Austria), AFFiRiS is developing immunotherapies to prevent chronic diseases. […]

June 29, 2016 - 2 minutesmins - By Denise Neves Gameiro

celyad c cure chart1 ischemic heart failure

News and Trends 29 Jun 2016

Cell Therapy for Heart Failure fails in Phase III … but not Entirely

Celyad failed to get significant results in its Phase III trial in cardiac disease. However, this cell therapy could still have a positive effect in a part of the patients. True potential or public relations patch? Cardiovascular diseases are the leading cause of death worldwide. Biotech solutions in the field range from gene therapy (with uniQure and […]

June 29, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 28 Jun 2016

And now, Immuno-oncology gets EMA’s pre-approval for Lung Cancer

MSD has received EMA pre-approval for its famous anti-PD-1 therapy, Keytruda. It could soon be used to treat non-small cell lung cancer (NSCLC), the deadliest type of cancer. Checkpoint inhibitors are a key strategy in the hype field of immuno-oncology. This kind of cancer therapy blocks the natural ‘safety checks’ of the immune system – […]

June 28, 2016 - 2 minutesmins - By Denise Neves Gameiro

molmed graft host disease zalmoxis leukemia

News and Trends 28 Jun 2016

Will the Leading Italian Biotech soon have its First Cell therapy on the Market?

MolMed has received conditional market approval for Zalmoxis, an ex vivo genetically engineered cell therapy that stops immune rejection of transplanted hematopoietic stem cells. This is a big step forward in a key treatment for blood cancers. A transplant of hematopoietic stem cells (cells that give origin to blood cells) is often used as part of treatments for […]

June 28, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 27 Jun 2016

CRISPR Therapeutics increases its Series B to a Massive €125M

Everyone wants to invest in CRISPR Therapeutics, it seems. The Basel and Cambridge, US biotech has raised more money for its ongoing Series B round, bringing the total to over €126M. The authorization for the first CRISPR trials have just arrived in the hands of the FDA, and this might have encouraged new investment. CRISPR Therapeutics […]

June 27, 2016 - 2 minutesmins - By Denise Neves Gameiro

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Denise Neves Gameiro

About

Articles by Denise Neves Gameiro

Danish Pharma enters in the Biologics arena with Antibody Buy-out

Novartis delivers German Biotech’s 12th Antibody to Clinics

“We have one of the World’s Most Advanced Functional HIV Cures under development”

Blood Wars and Celebrating the Unsung Rats of Science with #BioArt

37% of all Living Nobel Laureates urged Greenpeace to stop anti-GMO campaigns

Key German Hospital to start a Phase I trial in TCR Cell Therapy

11 Hot Companies to Meet this Year at BioSpain

Vienna-based Biotech raises €10M to fight Metabolic diseases and Parkinson’s

Cell Therapy for Heart Failure fails in Phase III … but not Entirely

And now, Immuno-oncology gets EMA’s pre-approval for Lung Cancer

Will the Leading Italian Biotech soon have its First Cell therapy on the Market?

CRISPR Therapeutics increases its Series B to a Massive €125M

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

About

Articles by Denise Neves Gameiro

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!